Jump to navigation Jump to search
Clodronic acid.png
Clinical data
AHFS/Drugs.comInternational Drug Names
ATC code
CAS Number
PubChem CID
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Molar mass244.892 g/mol
3D model (JSmol)

WikiDoc Resources for Clodronate


Most recent articles on Clodronate

Most cited articles on Clodronate

Review articles on Clodronate

Articles on Clodronate in N Eng J Med, Lancet, BMJ


Powerpoint slides on Clodronate

Images of Clodronate

Photos of Clodronate

Podcasts & MP3s on Clodronate

Videos on Clodronate

Evidence Based Medicine

Cochrane Collaboration on Clodronate

Bandolier on Clodronate

TRIP on Clodronate

Clinical Trials

Ongoing Trials on Clodronate at Clinical

Trial results on Clodronate

Clinical Trials on Clodronate at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Clodronate

NICE Guidance on Clodronate


FDA on Clodronate

CDC on Clodronate


Books on Clodronate


Clodronate in the news

Be alerted to news on Clodronate

News trends on Clodronate


Blogs on Clodronate


Definitions of Clodronate

Patient Resources / Community

Patient resources on Clodronate

Discussion groups on Clodronate

Patient Handouts on Clodronate

Directions to Hospitals Treating Clodronate

Risk calculators and risk factors for Clodronate

Healthcare Provider Resources

Symptoms of Clodronate

Causes & Risk Factors for Clodronate

Diagnostic studies for Clodronate

Treatment of Clodronate

Continuing Medical Education (CME)

CME Programs on Clodronate


Clodronate en Espanol

Clodronate en Francais


Clodronate in the Marketplace

Patents on Clodronate

Experimental / Informatics

List of terms related to Clodronate

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]


Clodronic acid (INN) or clodronate disodium (USAN) is a first generation (non-nitrogenous) bisphosphonate. It is an anti-osteoporotic drug approved for the prevention and treatment of osteoporosis in post-menopausal women and men to reduce vertebral fractures, hyperparathyroidism, hypercalcemia in malignancy, multiple myeloma and fracture related pain because of its potent anti-inflammatory and analgesic effects shown as a reduction in inflammatory markers like IL-1β, IL-6, and TNF-alfa.

An Italian study compared the analgesic effect of clodronic acid versus acetaminophen in reumatic condition related pain. Study result show a reduction in pain in favor of clodronic acid that provided more analgesia than 3 grams/day of acetaminophen. Clodronate is also used in experimental medicine to selectively deplete macrophages.

Clodronic acid is approved for human use in Canada and Australia, the United Kingdom, where it is marketed as Bonefos, Loron, Clodron and in Italy as Clasteon, Difosfonal, Osteostab and several generics. In other countries is prescribed as a bone resorption inhibitor and antihypercalcemic agent.

Use in equine medicine

Clodronic acid is approved for use in horses under the trade name Osphos, for treatment of navicular syndrome. It is given by intramuscular injection, with the total dose divided into 3 sites on the horse. Clinical effects may not be seen for up to 2 months, and horses may need treatments repeated every 3 to 6 months.

Adverse reactions and contraindications

Osphos has been shown to have several adverse effects. These include:

  • Signs of discomfort, agitation, or colic, usually within 2 hours of treatment.
  • Head shaking
  • Lip licking